计算溶液所需的质量、体积或浓度。
天然 级 提供 ≥85%(SDS-PAGE) 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存,避免反复冻融。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
载脂蛋白 A‑IV 是高密度脂蛋白(HDL)的次要蛋白组分,同时也与乳糜微粒相结合。该蛋白可通过抑制炎症发挥心血管疾病保护作用。
蛋白生物学作用
载脂蛋白 A‑IV(ApoA‑IV)是一种糖蛋白,主要由小肠在脂肪吸收过程中合成,为高密度脂蛋白与乳糜微粒的结构组分。其四螺旋束结构有助于脂质乳化,并可与载脂蛋白 B(apoB)相互作用,促进乳糜微粒的组装与分泌。餐后状态下,ApoA‑IV 从乳糜微粒上解离,进入无脂蛋白的血浆组分;在此处该蛋白可激活卵磷脂‑胆固醇酰基转移酶(LCAT),并通过载脂蛋白 C‑II 增强脂蛋白脂酶(LPL)活性,上述过程对富含甘油三酯脂蛋白的分解代谢至关重要。
常见研究用途
ApoA‑IV 可通过抑制 NF‑κB 通路、上调抗炎酶 DHCR24,抑制血管炎症,进而发挥心血管疾病(CVD)保护作用。APOA4 S347 等基因变异与冠心病(CHD)风险升高、血浆 ApoA‑IV 水平降低存在相关性。在代谢调控方面,ApoA‑IV 通过 PI3K‑Akt 通路刺激脂肪细胞 GLUT4 转位,改善胰岛素敏感性,同时可增强葡萄糖刺激的胰岛素分泌;该蛋白缺陷与糖耐量异常相关。长期高脂饮食会削弱其饱腹感信号,进而诱发肥胖;而 Roux‑en‑Y 胃旁路手术可提升 ApoA‑IV 水平,与体重下降及血糖改善相关。
临床中,ApoA‑IV 可作为冠心病风险与糖尿病进展的生物标志物。针对其抗炎、促胰岛素分泌及脂质调节特性开发的治疗策略,在代谢及心血管疾病领域具备应用前景。
常用于脂质代谢相关研究。
Apolipoprotein AIV is a minor protein component of HDL, Apo AIV is also associated with chylomicrons. It exhibits a protective role against cardiovascular disease by inhibiting inflammation.
Role of protein in biology
Apolipoprotein A-IV (ApoA-IV), a glycoprotein synthesized predominantly in the small intestine during fat absorption, is a structural component of HDL and chylomicrons. Its four-helix bundle architecture facilitates lipid emulsification and interaction with apolipoprotein B (apoB) to promote chylomicron assembly and secretion. Postprandially, ApoA-IV dissociates from chylomicrons into the lipoprotein-free plasma fraction, where it activates lecithin-cholesterol acyltransferase (LCAT) and enhances lipoprotein lipase (LPL) activity via apoC-II, critical for triglyceride-rich lipoprotein catabolism.
Common research uses
ApoA-IV exhibits protective roles against cardiovascular disease (CVD) by inhibiting vascular inflammation through NF-κB suppression and upregulating DHCR24, an anti-inflammatory enzyme. Genetic variants like APOA4 S347 correlate with elevated coronary heart disease (CHD) risk and reduced plasma ApoA-IV levels. In metabolic regulation, ApoA-IV improves insulin sensitivity by stimulating GLUT4 translocation in adipocytes via PI3K-Akt pathways and enhances glucose-stimulated insulin secretion, with deficiencies linked to glucose intolerance. Chronic high-fat diets blunt its satiety signaling, contributing to obesity, while Roux-en-Y gastric bypass increases ApoA-IV, correlating with weight loss and improved glucose control.
Clinically, ApoA-IV serves as a biomarker for CHD risk and diabetes progression. Therapeutic strategies targeting its anti-inflammatory, insulinotropic, and lipid-modulating properties show promise for metabolic and cardiovascular disorders.
Common uses include lipid metabolism studies.